GGrantIndex
← Search

CORE--HEMATOPOIETIC STEM CELL FACILITY

$78,870P30FY2002CANIH

Case Western Reserve University, Cleveland OH

Investigators

Linked publications, trials & patents

Trial NCT05340673Trial NCT05198830Trial NCT02590107Trial NCT02535325Trial NCT02451124Trial NCT02419846Trial NCT02417948Trial NCT02392377Trial NCT02388932Trial NCT02383433Trial NCT02375477Trial NCT02354326Trial NCT02345460Trial NCT02342730Trial NCT02337465Trial NCT02327390Trial NCT02319889Trial NCT02307474Trial NCT02287636Trial NCT02252393Trial NCT02181478Trial NCT02179762Trial NCT02163317Trial NCT02158767Trial NCT02153450Trial NCT02135562Trial NCT02131207Trial NCT02129582Trial NCT02129569Trial NCT02129517Trial NCT02129218Trial NCT02128373Trial NCT02108587Trial NCT02100423Trial NCT02084147Trial NCT02082405Trial NCT02081794Trial NCT02079155Trial NCT02073097Trial NCT02073045Trial NCT02071901Trial NCT02070458Trial NCT02070419Trial NCT02055586Trial NCT02037048Trial NCT01973062Trial NCT01959490Trial NCT01959477Trial NCT01954784Trial NCT01954732Trial NCT01951885Trial NCT01939028Trial NCT01928485Trial NCT01894061Trial NCT01408043Trial NCT00991991Trial NCT00970684Trial NCT00961220Trial NCT00956475Trial NCT00952939Trial NCT00949247Trial NCT00945061Trial NCT00941720Trial NCT00941070Trial NCT00939510Trial NCT00918892Trial NCT00918788Trial NCT00918658Trial NCT00918216Trial NCT00910039Trial NCT00909662Trial NCT00908739Trial NCT00908141Trial NCT00907699Trial NCT00905086Trial NCT00900133Trial NCT00899158Trial NCT00899132Trial NCT00898573Trial NCT00898274Trial NCT00897143Trial NCT00892385Trial NCT00873600Trial NCT00873002Trial NCT00866320Trial NCT00856115Trial NCT00853021Trial NCT00842452Trial NCT00809185Trial NCT00796978Trial NCT00795678Trial NCT00769951Trial NCT00769249Trial NCT00752323Trial NCT00740961Trial NCT00736216Trial NCT00735514Trial NCT00733252Trial NCT00732745Trial NCT00732173

Abstract

DESCRIPTION (provided by applicant): The Hematopoietic Stem Cell Core Facility (HSC Core) serves as a resource for procurement and processing of human hematopoietic cells derived from a variety of sources, and routine phenotypic and functional characterization of these cells for the members of the Cancer Center. The HSC Core objectives are 1) to provide standard assays of hematopoiesis and specifically stem cell analysis for evolution of reconstitution after transplantation. The facility serves as a quality control/assurance laboratory for translational clinical trials of blood and marrow transplantation, 2) to procure and distribute human blood and marrow cells so as to promote translational research efforts in hematopoiesis and for biochemical endpoints within the Developmental Therapeutics Program. The HSC Core collects, processes, and distributes peripheral blood, bone marrow and umbilical cord blood samples from normal donors and patients according to an IRB approved protocol. The facility routinely performs 14 day CFU-GM, BFU-E, CFU-GEMM, and CFU megakarocytic progenitor assays, Long-Term (5-week) Culture Initiating Cell (LTC-IC) assay, separation of mononuclear cells by density gradient (Ficoll-Hypaque or Percoll), adherence depletion of mononuclear cells, CD34+ cell enrichment with VarioMACS system, and mesenchymal stem cell culture purification. The HSC Core Facility also maintains a variety of murine and human hematopoietic cytokines and provides consultation to investigators working with hematopoietic cells. The HSC Core Facility is planning to implement real time measurement of absolute numbers of CD34+ cells using IMGN2000 device and clinical scale G-CSF mobilized peripheral blood collections from normal donors for preclinical and basic research purposes.

View original record on NIH RePORTER →